Activation of voltage-gated KCNQ/Kv7 channels by anticonvulsant retigabine attenuates mechanical allodynia of inflammatory temporomandibular joint in rats

Molecular Pain

Volumn 6, Issue , 2010, Pages

  Xu, Wen ^a   Wu, Yuwei ^b   Bi, Yeping ^a   Tan, Lei ^a   Gan, Yehua ^b   Wang, KeWei ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY SCHOOL AND HOSPITAL OF STOMATOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

10,10 BIS(4 PYRIDINYLMETHYL) 9(10H) ANTHRACENONE; MORPHINE; POTASSIUM CHANNEL KCNQ; RETIGABINE; 10,10-BIS(4-PYRIDINYLMETHYL)-9(10H)-ANTHRACENONE; ANTHRACENE DERIVATIVE; ANTICONVULSIVE AGENT; CARBAMIC ACID DERIVATIVE; FREUND ADJUVANT; PHENYLENEDIAMINE DERIVATIVE;

ADJUVANT ARTHRITIS; ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; CHANNEL GATING; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; FOOD INTAKE; HISTOPATHOLOGY; MALE; MECHANICAL STIMULATION; MYOFASCIAL PAIN; NERVE CELL EXCITABILITY; NONHUMAN; PAIN THRESHOLD; POTASSIUM CURRENT; PRIORITY JOURNAL; RAT; SENSITIZATION; SPRAGUE DAWLEY RAT; STIMULUS RESPONSE; WITHDRAWAL REFLEX; ANALGESIA; ANIMAL; FEEDING BEHAVIOR; HYPERALGESIA; INFLAMMATION; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TEMPOROMANDIBULAR JOINT;

ANALGESIA; ANIMALS; ANTHRACENES; ANTICONVULSANTS; CARBAMATES; FEEDING BEHAVIOR; FREUND'S ADJUVANT; HYPERALGESIA; INFLAMMATION; INJECTIONS, INTRAVENTRICULAR; ION CHANNEL GATING; KCNQ POTASSIUM CHANNELS; MALE; PHENYLENEDIAMINES; RATS; RATS, SPRAGUE-DAWLEY; TEMPOROMANDIBULAR JOINT;

EID: 77955961747     PISSN: 17448069     EISSN: None     Source Type: Journal    
DOI: 10.1186/1744-8069-6-49     Document Type: Article

References (48)

1. Brazeau GA, et al. The role of pharmacy in the management of patients with temporomandibular disorders and orofacial pain. J Am Pharm Assoc (Wash) 1998, 38(3):354-61. quiz 362-3.
2. Sarlani E, et al. Evidence for up-regulated central nociceptive processing in patients with masticatory myofascial pain. J Orofac Pain 2004, 18(1):41-55.
3. de Leeuw R, et al. The contribution of neuroimaging techniques to the understanding of supraspinal pain circuits: implications for orofacial pain. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005, 100(3):308-14. 10.1016/j.tripleo.2004.11.014, 16122658.
4. Denucci DJ, Dionne RA, Dubner R. Identifying a neurobiologic basis for drug therapy in TMDs. J Am Dent Assoc 1996, 127(5):581-93.
5. Sarlani E, Greenspan JD. Why look in the brain for answers to temporomandibular disorder pain?. Cells Tissues Organs 2005, 180(1):69-75. 10.1159/000086200, 16088135.
6. Rogawski MA, Bazil CW. New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels. Curr Neurol Neurosci Rep 2008, 8(4):345-52. 10.1007/s11910-008-0053-7, 2587091, 18590620.
7. Hersh EV, Balasubramaniam R, Pinto A. Pharmacologic management of temporomandibular disorders. Oral Maxillofac Surg Clin North Am 2008, 20(2):197-210. vi, 10.1016/j.coms.2007.12.005, 18343325.
8. Kimos P, et al. Analgesic action of gabapentin on chronic pain in the masticatory muscles: a randomized controlled trial. Pain 2007, 127(1-2):151-60. 10.1016/j.pain.2006.08.028, 17030096.
9. Blackburn-Munro G, Jensen BS. The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. Euro J Pharmacol 2003, 460:109-116.
10. Passmore GM, et al. KCNQ/M currents in sensory neurons: significance for pain therapy. J Neurosci 2003, 23(18):7227-36.
11. Dost R, Rostock A, Rundfeldt C. The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation. Naunyn Schmiedebergs Arch Pharmacol 2004, 369(4):382-90. 10.1007/s00210-004-0881-1, 15007538.
12. Nielsen AN, Mathiesen C, Blackburn-Munro G. Pharmacological characterisation of acid-induced muscle allodynia in rats. Eur J Pharmacol 2004, 487(1-3):93-103. 10.1016/j.ejphar.2004.01.017, 15033380.
13. Hirano K, et al. Kv7.2-7.5 voltage-gated potassium channel (KCNQ2-5) opener, retigabine, reduces capsaicin-induced visceral pain in mice. Neurosci Lett 2007, 413(2):159-62. 10.1016/j.neulet.2006.11.043, 17184917.
14. Lang PM, et al. Retigabine reduces the excitability of unmyelinated peripheral human axons. Neuropharmacology 2008, 54(8):1271-8. 10.1016/j.neuropharm.2008.04.006, 18474382.
15. Roza C, Lopez-Garcia JA. Retigabine, the specific KCNQ channel opener, blocks ectopic discharges in axotomized sensory fibres. Pain 2008, 138(3):537-45. 10.1016/j.pain.2008.01.031, 18331780.
16. Rundfeldt C, Netzer R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits. Neurosci Lett 2000, 282(1-2):73-6. 10.1016/S0304-3940(00)00866-1, 10713399.
17. Wang HS, et al. KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science 1998, 282(5395):1890-3. 10.1126/science.282.5395.1890, 9836639.
18. Wickenden AD, et al. Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells. Br J Pharmacol 2001, 132(2):381-4. 10.1038/sj.bjp.0703861, 1572592, 11159685.
19. Schroder RL, et al. KCNQ4 channel activation by BMS-204352 and retigabine. Neuropharmacology 2001, 40(7):888-98. 10.1016/S0028-3908(01)00029-6, 11378159.
20. Cooper EC, Jan LY. M-channels: neurological diseases, neuromodulation, and drug development. Arch Neurol 2003, 60(4):496-500. 10.1001/archneur.60.4.496, 12707061.
21. Brown BS, Yu SP. Modulation and genetic identification of the M channe. Progress in Biophysics & Molecular Biology 2000, 73:135-166.
22. Armand V, Rundfeldt C, Heinemann U. Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by low magnesium in rat entorhinal cortex hippocampal slices. Epilepsia 2000, 41(1):28-33. 10.1111/j.1528-1157.2000.tb01501.x, 10643920.
23. Mejersjo C, Wenneberg B. Diclofenac sodium and occlusal splint therapy in TMJ osteoarthritis: a randomized controlled trial. J Oral Rehabil 2008, 35(10):729-38. 10.1111/j.1365-2842.2008.01863.x, 18482350.
24. Peretz A, et al. Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. Mol Pharmacol 2005, 67(4):1053-66. 10.1124/mol.104.007112, 15598972.
25. Takeda M, et al. Temporomandibular joint inflammation potentiates the excitability of trigeminal root ganglion neurons innervating the facial skin in rats. J Neurophysiol 2005, 93(5):2723-38. 10.1152/jn.00631.2004, 15625101.
26. Wu YW, et al. 17-Beta-estradiol enhanced allodynia of inflammatory temporomandibular joint through upregulation of hippocampal TRPV1 in ovariectomized rats. J Neurosci 30(26):8710-9. 10.1523/JNEUROSCI.6323-09.2010, 20592193.
27. Ren K. An improved method for assessing mechanical allodynia in the rat. Physiol Behav 1999, 67(5):711-6. 10.1016/S0031-9384(99)00136-5, 10604842.
28. Guan G, et al. Estrogenic effect on swelling and monocytic receptor expression in an arthritic temporomandibular joint model. J Steroid Biochem Mol Biol 2005, 97(3):241-50. 10.1016/j.jsbmb.2005.05.013, 16153820.
29. Kardel R, et al. Inflammatory cell and cytokine patterns in patients with chronic polyarthritis and temporomandibular joint involvement. Acta Odontol Scand 2006, 64(4):221-6. 10.1080/00016350600573183, 16829497.
30. Harper RP, et al. Meal pattern analysis in response to temporomandibular joint inflammation in the rat. J Dent Res 2000, 79(9):1704-11. 10.1177/00220345000790091101, 11023267.
31. Kerins CA, et al. Meal pattern changes associated with temporomandibular joint inflammation/pain in rats; analgesic effects. Pharmacol Biochem Behav 2003, 75(1):181-9. 10.1016/S0091-3057(03)00072-8, 12759126.
32. Takeda M, et al. Activation of NK1 receptor of trigeminal root ganglion via substance P paracrine mechanism contributes to the mechanical allodynia in the temporomandibular joint inflammation in rats. Pain 2005, 116(3):375-85. 10.1016/j.pain.2005.05.007, 15985331.
33. Takeda M, et al. Enhanced excitability of rat trigeminal root ganglion neurons via decrease in A-type potassium currents following temporomandibular joint inflammation. Neuroscience 2006, 138(2):621-30. 10.1016/j.neuroscience.2005.11.024, 16387448.
34. Brown DA, Passmore GM. Neural KCNQ (Kv7) channels. Br J Pharmacol 2009, 156(8):1185-95. 10.1111/j.1476-5381.2009.00111.x, 2697739, 19298256.
35. Brown DA, Adams PR, Brown DA, Passmore GM. Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neurone. Nature 1980, 283(5748):673-6. 10.1038/283673a0, 6965523.
36. Charlier C, et al. A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family [see comments]. Nature Genetics 1998, 18(1):53-5. 10.1038/ng0198-53, 9425900.
37. Biervert C, et al. A potassium channel mutation in neonatal human epilepsy. Science 1998, 279(5349):403-6. 10.1126/science.279.5349.403, 9430594.
38. Schroeder BC, et al. KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents. J Biol Chem 2000, 275(31):24089-95. 10.1074/jbc.M003245200, 10816588.
39. Cooper EC, et al. M channel KCNQ2 subunits are localized to key sites for control of neuronal network oscillations and synchronization in mouse brain. J Neurosci 2001, 21(24):9529-40.
40. Cooper EC, et al. Immunohistochemical analysis of KCNQ3 potassium channels in mouse brain. Neurosci Lett 2006, 400(1-2):101-4. 10.1016/j.neulet.2006.02.017, 16513263.
41. Rundfeldt C, Geiger J, et al. The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells. Eur J Pharmacol 1997, 336(2-3):243-9. 10.1016/S0014-2999(97)01249-1, 9384239.
42. Peters HC, et al. Conditional transgenic suppression of M channels in mouse brain reveals functions in neuronal excitability, resonance and behavior. Nat Neurosci 2005, 8(1):51-60. 10.1038/nn1375, 15608631.
43. Rostock A, et al. D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res 1996, 23(3):211-23. 10.1016/0920-1211(95)00101-8, 8739124.
44. Holmlund A, Hellsing G, Axelsson S. The temporomandibular joint: a comparison of clinical and arthroscopic findings. J Prosthet Dent 1989, 62(1):61-5. 10.1016/0022-3913(89)90051-6, 2746544.
45. Murakami K, et al. Correlation between pain and synovitis in patients with internal derangement of the temporomandibular joint. J Oral Maxillofac Surg 1991, 49(11):1159-61. discussion 1162, 10.1016/0278-2391(91)90407-D, 1941329.
46. Israel HA, et al. Correlation between arthroscopic diagnosis of osteoarthritis and synovitis of the human temporomandibular joint and keratan sulfate levels in the synovial fluid. J Oral Maxillofac Surg 1997, 55(3):210-7. discussion 217-8, 10.1016/S0278-2391(97)90526-7, 9054908.
47. Kopp S. The influence of neuropeptides, serotonin, and interleukin 1beta on temporomandibular joint pain and inflammation. J Oral Maxillofac Surg 1998, 56(2):189-91. 10.1016/S0278-2391(98)90867-9, 9461143.
48. Streng T, Christoph T, Andersson KE. Urodynamic effects of the K+ channel (KCNQ) opener retigabine in freely moving, conscious rats. J Urol 2004, 172(5 Pt 1):2054-8. 10.1097/01.ju.0000138155.33749.f4, 15540788.